Another RAGE blocking agent currently in Phase III clinical trials in Alzheimer's disease is the small molecule Azeliragon, which inhibits the receptor for advanced glycation endproducts through its first extracellular V-type domain, which prevents RAGE ligands from interacting with RAGE. Here, AGER is linked to early-onset autosomal dominant Alzheimer disease.